Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasms 4 Neoplasm Metastasis 3 Lung Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Sarcoma 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Rare Tumor 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms, Unknown Primary 1 Neoplasms by Site 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Genomic Instability 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × alectinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡